This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
216
Change from baseline in 17-Item Hamilton Depression Rating Scale (HAM-D17) total score at Day 15
The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement.
Time frame: 15 days
Change from baseline in HAM-D17 total score at Day 29
The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement.
Time frame: 29 days
Change from baseline in HAM-D17 total score at all other time points
The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement.
Time frame: 8 days, 22 days, 36 days, and 43 days
Change from baseline in Clinical Global Impression-Severity (CGI-S) score at Day 15 and all other time points
The CGI-S assesses the clinician's impression of the participant's current depression symptoms. The clinician should use his/her total clinical experience with this patient population and rate the current severity of the participant's mental illness on a 7-point scale from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).
Time frame: 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Praxis Research Site
Phoenix, Arizona, United States
Praxis Research Site
Garden Grove, California, United States
Praxis Research Site
Lafayette, California, United States
Praxis Research Site
Lemon Grove, California, United States
Praxis Research Site
Oceanside, California, United States
Praxis Research Site
Pico Rivera, California, United States
Praxis Research Site
Redlands, California, United States
Praxis Research Site
Jacksonville, Florida, United States
Praxis Research Site
Orange City, Florida, United States
Praxis Research Site
Orlando, Florida, United States
...and 21 more locations
Clinical Global Impression-Improvement (CGI-I) score at Day 15 and all other time points
The CGI-I assesses the participant's improvement (or worsening). The clinician is required to assess the participant's condition relative to Baseline (Day 1) on a 7-point scale from 1 (Very much improved) to 7 (Very much worse).
Time frame: 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
HAM-D17 response (reduction from baseline score of ≥50%) at Day 15, Day 29, and all other time points
The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement.
Time frame: 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
HAM-D17 remission (total score of ≤7) at Day 15, Day 29, and all other time points
The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement.
Time frame: 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Change from baseline in the Symptoms of Depression Questionnaire (SDQ) total and sub-scale scores at Day 15 and all other time points
The SDQ is a 44-item, self-report scale assessing the severity of symptoms across several subtypes of depression. Items are scored on a 7-point scale (ranging from 1 to 6). The SDQ total score is the sum of all 44 item scores and ranges from 44 to 264 with higher scores indicating worse symptoms.
Time frame: 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Patient Global Impression-Improvement (PGI-I) score at Day 15 and all other time points
The PGI-I scale is a global self-assessment used to rate the response of a participant's condition to therapy or intervention. It consists of 1 question that asks the participant to rate their current condition compared to how it was prior to beginning treatment on a scale of 1 (very much better) to 7 (very much worse).
Time frame: 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Change from baseline in the Work and Social Adjustment Scale (WSAS) at Day 15 and all other time points
The WSAS assesses the degree to which mental health problems interfere with day-to-day functioning in 5 domains: work, social leisure activities, private leisure activities, home- management, and personal relationships. The WSAS total score is the sum of the 5 item scores and ranges from 0 to 40, with higher scores indicating poorer adjustment.
Time frame: 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Change from baseline in the 12-Item Short Form Survey (SF-12) at Day 15 and all other time points
The SF-12 is composed of 12 questions covering 8 dimensions of health: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Total scores range from 0 (worse health) to 100 (better health).
Time frame: 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Incidence and severity of Adverse Events (AE)
An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study drug, whether or not considered related to the study drug.
Time frame: 43 days
Incidence of AEs by preferred term
The incidence of AEs will be reported by preferred term, including any terms related to clinically significant changes in body temperature, pulse rate, respiratory rate, blood pressure (systolic and diastolic), clinical laboratory measures (chemistry, hematology, urinalysis, and coagulation), and electrocardiogram parameters (heart rate, PR, QRS, QT, and corrected QT intervals).
Time frame: Up to 43 days
Incidence of Columbia-Suicide Severity Rating Scale (C-SSRS) measured suicidal ideation or behavior
The C-SSRS is composed of 5 yes/no questions addressing suicidal behavior and 5 yes/no questions addressing suicidal ideation, with sub-questions assessing the severity. Incidence is measured as the number of "yes" answers indicating the presence of suicidal ideation or behavior.
Time frame: Up to 43 days